Low oxygen tension enhances hepatitis C virus replication

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2935-2948

  Vassilaki, N ^a   Kalliampakou, K I ^a   Kotta Loizou, I ^a   Befani, C ^b   Liakos, P ^b   Simos, G ^b   Mentis, A F ^a   Kalliaropoulos, A ^a   Doumba, P P ^c   Smirlis, D ^a   Foka, P ^a   Bauhofer, O ^d   Poenisch, M ^d   Windisch, M P ^e   Lee, M E ^e   Koskinas, J ^c   Bartenschlager, R ^d   Mavromaraa, P ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c HIPPOKRATION HOSPITAL   (Greece)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Institute Pasteur Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE ISOENZYME; HEXOKINASE; HEXOKINASE 2; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; UNCLASSIFIED DRUG; VASCULOTROPIN A; VIRUS RNA;

ANAEROBIC METABOLISM; ARTICLE; CELL ENERGY; CELL GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; GLYCOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; OXYGEN TENSION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; RNA TRANSLATION; UPREGULATION; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION;

CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; CREATINE KINASE; GENOME, VIRAL; GLYCOLYSIS; HEPACIVIRUS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; KINESIN; L-LACTATE DEHYDROGENASE; LIVER; LIVER NEOPLASMS; OXYGEN; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, VIRAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84874699537     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02534-12     Document Type: Article

References (88)

1. Levrero M. 2006. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:3834-3847.
2. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35-S46.
3. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972.
4. Moradpour D, Penin F, Rice CM. 2007. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5:453-463.
5. Tang H, Grise H. 2009. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci. (Lond.) 117:49-65.
6. Eng FJ, Walewski JL, Klepper AL, Fishman SL, Desai SM, McMullan LK, Evans MJ, Rice CM, Branch AD. 2009. Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J. Virol. 83:3104-3114.
7. Vassilaki N, Mavromara P. 2009. The HCV ARFP/F/core+1 protein: production and functional analysis of an unconventional viral product. IUBMB Life 61:739-752.
8. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
9. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
10. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
11. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413.
12. Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R. 2007. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J. Virol. 81:13168-13179.
13. Ashfaq UA, Khan SN, Nawaz Z, Riazuddin S. 2011. In-vitro model systems to study hepatitis C virus. Genet. Vaccines Ther. 9:7.
14. de Groot H, Noll T. 1987. Oxygen gradients: the problem of hypoxia. Biochem. Soc. Trans. 15:363-365.
15. Fleckenstein W, Weiss C. 1984. Ein neues Gewebe-pO2-Messverfahren zum Nachweis von Mikrozirkulationsstorungen. Focus Med. Hochschule Lubeck. 1:74-84.
16. Jungermann K, Kietzmann T. 2000. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 31:255-260.
17. Torre C, Perret C, Colnot S. 2010. Molecular determinants of liver zonation. Prog. Mol. Biol. Transl. Sci. 97:127-150.
18. Semenza GL. 2011. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365:537-547.
19. Martinez I, Nedredal GI, Oie CI, Warren A, Johansen O, Le Couteur DG, Smedsrod B. 2008. The influence of oxygen tension on the structure and function of isolated liver sinusoidal endothelial cells. Comp. Hepatol. 7:4.
20. Aghi MK, Liu TC, Rabkin S, Martuza RL. 2009. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol. Ther. 17:51-56.
21. Connor JH, Naczki C, Koumenis C, Lyles DS. 2004. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J. Virol. 78:8960-8970.
22. Haque M, Davis DA, Wang V, Widmer I, Yarchoan R. 2003. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia. J. Virol. 77: 6761-6768.
23. Pillet S, Le Guyader N, Hofer T, NguyenKhac F, Koken M, Aubin JT, Fichelson S, Gassmann M, Morinet F. 2004. Hypoxia enhances human B19 erythrovirus gene expression in primary erythroid cells. Virology 327: 1-7.
24. Polonis VR, Anderson GR, Vahey MT, Morrow PJ, Stoler D, Redfield RR. 1991. Anoxia induces human immunodeficiency virus expression in infected T cell lines. J. Biol. Chem. 266:11421-11424.
25. Riedinger HJ, van Betteraey M, Probst H. 1999. Hypoxia blocks in vivo initiation of simian virus 40 replication at a stage preceding origin unwinding. J. Virol. 73:2243-2252.
26. Shen BH, Hermiston TW. 2005. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther. 12:902-910.
27. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014.
28. Friebe P, Boudet J, Simorre JP, Bartenschlager R. 2005. Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J. Virol. 79:380-392.
29. Werth N, Beerlage C, Rosenberger C, Yazdi AS, Edelmann M, Amr A, Bernhardt W, von Eiff C, Becker K, Schafer A, Peschel A, Kempf VA. 2010. Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS One 5:e11576. doi:10.1371 /journal.pone.0011576.
30. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, Nagayama K, Tanaka T, Wakita T. 2001. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 64:334-339.
31. Schmitt M, Scrima N, Radujkovic D, Caillet-Saguy C, Simister PC, Friebe P, Wicht O, Klein R, Bartenschlager R, Lohmann V, Bressanelli S. 2011. A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. J. Virol. 85:2565-2581.
32. Vassilaki N, Friebe P, Meuleman P, Kallis S, Kaul A, Paranhos-Baccala G, Leroux-Roels G, Mavromara P, Bartenschlager R. 2008. Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication. J. Virol. 82:11503-11515.
33. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A, Georgatsou E, Bonanou S, Simos G. 2006. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1α. J. Biol. Chem. 281:33095-33106.
34. Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. 2002. Promoter specificity and biological activity of tethered AP-1 dimers. Mol. Cell. Biol. 22:4952-4964.
35. Vassilaki N, Boleti H, Mavromara P. 2008. Expression studies of the HCV-1a core+1 open reading frame in mammalian cells. Virus Res. 133: 123-135.
36. Zhou W, Dosey TL, Biechele T, Moon RT, Horwitz MS, Ruohola-Baker H. 2011. Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct. PLoS One 6:e27460. doi:10.1371/journal.pone.0027460.
37. Woerz I, Lohmann V, Bartenschlager R. 2009. Hepatitis C virus replicons: dinosaurs still in business? J. Viral Hepat. 16:1-9.
38. Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, Lohmann V. 2007. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J. Virol. 81:5270-5283.
39. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. 2006. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21:521-531.
40. Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF. 2010. Hepatitis C virus controls interferon production through PKR activation. PLoS One 5:e10575. doi:10.1371/journal.pone.0010575.
41. Bracken CP, Fedele AO, Linke S, Balrak W, Lisy K, Whitelaw ML, Peet DJ. 2006. Cell-specific regulation of hypoxia-inducible factor (HIF)-1α and HIF-2α stabilization and transactivation in a graded oxygen environment. J. Biol. Chem. 281:22575-22585.
42. Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A. 2007. Hepatitis C virus stabilizes hypoxia-inducible factor 1α and stimulates the synthesis of vascular endothelial growth factor. J. Virol. 81:10249-10257.
43. Ripoli M, d'aprile A, Quarato G, Sarasin-Filipowicz M, Gouttenoire J, Scrima R, Cela O, Boffoli D, Heim MH, Moradpour D, Capitanio N, Piccoli C. 2010. Hepatitis C virus-linked mitochondrial dysfunction promotes hypoxia-inducible factor 1α-mediated glycolytic adaptation. J. Virol. 84:647-660.
44. Wilson GK, Brimacombe CL, Rowe IA, Reynolds GM, Fletcher NF, Stamataki Z, Bhogal RH, Simoes ML, Ashcroft M, Afford SC, Mitry RR, Dhawan A, Mee CJ, Hubscher SG, Balfe P, McKeating JA. 2012. A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J. Hepatol. 56:803-809.
45. Loboda A, Jozkowicz A, Dulak J. 2010. HIF-1 and HIF-2 transcription factors-similar but not identical. Mol. Cells 29:435-442.
46. Nagel S, Talbot NP, Mecinovic J, Smith TG, Buchan AM, Schofield CJ. 2010. Therapeutic manipulation of the HIF hydroxylases. Antioxid. Redox Signal. 12:481-501.
47. Webster KA. 2003. Evolution of the coordinate regulation of glycolytic enzyme genes by hypoxia. J. Exp. Biol. 206:2911-2922.
48. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. 2005. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol. 42:358-364.
49. Lee SH, Lee MY, Lee JH, Han HJ. 2008. A potential mechanism for short time exposure to hypoxia-induced DNA synthesis in primary cultured chicken hepatocytes: correlation between Ca(2+)/PKC/MAPKs and PI3K/Akt/mTOR. J. Cell. Biochem. 104:1598-1611.
50. Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. 2001. Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 20:7624-7634.
51. Govorova LV, Teplov SI. 1976. Changes in the creatine kinase activity of the brain, heart, liver and plasma of rats subjected to oxygen starvation. Biull. Eksp. Biol. Med. 81:177-179. (In Russian.)
52. Miller K, Halow J, Koretsky AP. 1993. Phosphocreatine protects transgenic mouse liver expressing creatine kinase from hypoxia and ischemia. Am. J. Physiol. 265:C1544-C1551.
53. Pruksakorn D, Lirdprapamongkol K, Chokchaichamnankit D, Subhasitanont P, Chiablaem K, Svasti J, Srisomsap C. 2010. Metabolic alteration of HepG2 in scaffold-based 3-D culture: proteomic approach. Proteomics 10:3896-3904.
54. Wyss M, Kaddurah-Daouk R. 2000. Creatine and creatinine metabolism. Physiol. Rev. 80:1107-1213.
55. Hara H, Aizaki H, Matsuda M, Shinkai-Ouchi F, Inoue Y, Murakami K, Shoji I, Kawakami H, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T. 2009. Involvement of creatine kinase B in hepatitis C virus genome replication through interaction with the viral NS4A protein. J. Virol. 83:5137-5147.
56. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. 2012. Persistence ofHCVin quiescent hepatic cells under conditions of an interferon-induced antiviral response. Gastroenterology 143:429-438.e8. doi:10.1053/j.gastro.2012.04.018.
57. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. 2004. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64:3892-3899.
58. Kim JW, Dang CV. 2006. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66:8927-8930.
59. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. 2007. Hypoxiainducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27:7381-7393.
60. Levine AJ, Puzio-Kuter AM. 2010. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340-1344.
61. Michiels C, Minet E, Michel G, Mottet D, Piret JP, Raes M. 2001. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life 52:49-53.
62. Pelicano H, Martin DS, Xu RH, Huang P. 2006. Glycolysis inhibition for anticancer treatment. Oncogene 25:4633-4646.
63. Polytarchou C, Iliopoulos D, Hatziapostolou M, Kottakis F, Maroulakou I, Struhl K, Tsichlis PN. 2011. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation. Cancer Res. 71:4720-4731.
64. Lee CJ, Liao CL, Lin YL. 2005. Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection. J. Virol. 79:8388-8399.
65. Zhu YZ, Cao MM, Wang WB, Wang W, Ren H, Zhao P, Qi ZT. 2012. Association of heat-shock protein 70 with lipid rafts is required for Japanese encephalitis virus infection in Huh7 cells. J. Gen. Virol. 93:61-71.
66. Michalopoulos GK, DeFrances MC. 1997. Liver regeneration. Science 276:60-66.
67. Chen AY, Kleiboeker S, Qiu J. 2011. Productive parvovirus B19 infection of primary human erythroid progenitor cells at hypoxia is regulated by STAT5A and MEK signaling but not HIFα. PLoS Pathog. 7:e1002088. doi: 10.1371/journal.ppat.1002088.
68. Racker E. 1974. History of the Pasteur effect and its pathobiology. Mol. Cell. Biochem. 5:17-23.
69. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033.
70. Walters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, Rice CM, Katze MG. 2009. Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog. 5:e1000269. doi:10.1371/journal.ppat.1000269.
71. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Buhler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45.
72. Wu X, Zhou Y, Zhang K, Liu Q, Guo D. 2008. Isoform-specific interaction of pyruvate kinase with hepatitis C virus NS5B. FEBS Lett. 582: 2155-2160.
73. Discher DJ, Bishopric NH, Wu X, Peterson CA, Webster KA. 1998. Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J. Biol. Chem. 273:26087-26093.
74. Hoque M, Mathews MB, Pe'ery T. 2010. Progranulin (granulin/epithelin precursor) and its constituent granulin repeats repress transcription from cellular promoters. J. Cell. Physiol. 223:224-233.
75. Wyatt E, Wu R, Rabeh W, Park HW, Ghanefar M, Ardehali H. 2010. Regulation and cytoprotective role of hexokinase III. PLoS One 5:e13823. doi:10.1371/journal.pone.0013823.
76. Fruehauf JP, Meyskens FL, Jr. 2007. Reactive oxygen species: a breath of life or death? Clin. Cancer Res. 13:789-794.
77. Mizukami Y, Kohgo Y, Chung DC. 2007. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res. 13:5670-5674.
78. Zeng M, Kikuchi H, Pino MS, Chung DC. 2010. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One 5:e10966. doi:10.1371/journal.pone .0010966.
79. Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, Hikita H, Hiramatsu N, Kanto T, Hayashi N, Takehara T. 2011. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem. Biophys. Res. Commun. 412:92-97.
80. Kang SM, Lim S, Won SJ, Shin YJ, Lim YS, Ahn BY, Hwang SB. 2011. c-Fos regulates hepatitis C virus propagation. FEBS Lett. 585:3236-3244.
81. Kim K, Kim KH, Kim HY, Cho HK, Sakamoto N, Cheong J. 2010. Curcumin inhibits hepatitis C virus replication via suppressing the Akt- SREBP-1 pathway. FEBS Lett. 584:707-712.
82. Pfannkuche A, Buther K, Karthe J, Poenisch M, Bartenschlager R, Trilling M, Hengel H, Willbold D, Haussinger D, Bode JG. 2011. C-Src is required for complex formation between the hepatitis C virus-encoded proteins NS5A and NS5B: a prerequisite for replication. Hepatology 53: 1127-1136.
83. Zhang Z, Harris D, Pandey VN. 2008. The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J. Virol. 82:5761-5773.
84. Meffert G, Gellerich FN, Margreiter R, Wyss M. 2005. Elevated creatine kinase activity in primary hepatocellular carcinoma. BMC Gastroenterol. 5:9.
85. Firth JD, Ebert BL, Ratcliffe PJ. 1995. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J. Biol. Chem. 270:21021-21027.
86. Teicher BA, Menon K, Northey D, Liu J, Kufe DW, Kaddurah-Daouk R. 1995. Cyclocreatine in cancer chemotherapy. Cancer Chemother. Pharmacol. 35:411-416.
87. Tennant DA, Duran RV, Gottlieb E. 2010. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer. 10:267-277.
88. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. 2008. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11-20.